GAIA BioMedicine, Inc., founded in 2015 as a spin-off venture of Kyushu University, is a technology-driven biopharmaceutical company specializing in cell therapies and immunotherapies, mainly for intractable malignancies.
Our mission and vision are reflected in the company name, GAIA, as we fight intractable diseases using the power of Genes and the Immune system as the rod of Asclepius the Greek god of medicine.
A platform to produce highly active NK-like cells that can eliminate solid tumors
・off-the-shelf, allogeneic cell-based
・more rapid and effective tumor-killing activity than that of currently available CAR-T cells
A peptide platform that allows GAIA NK-like cells to maintain their active state in vivo and target specific proteins (e.g., HER2) that are exclusively expressed by cancer cells
・GAAAP enables the generation of a wide array of antibody-armed GAIA NK-like cells
・GAAAP dramatically reduces on-target, off-tumor side effects due to antibody-dependent opsonization